In order to obtain an international standarization of acupuncture point localization it is necessary to first establish a standard local scale. In original texts the body height is given as 75 cun and the anterior and lateral lengths of each part of the body are indicated. This research required a standard local scale for the thigh area however this is divided into medial and lateral sides. On the medial side the scale is determined as 18 cun measured from the superior ridge of the pubic symphysis to the superior ridge of the medial epicondyle of the femur. However if this is not changed to the knee joint split line it is difficult to divide it into acupuncture points. Actual measurement tp the knee joint split was calculated at 20 cun. The standard scale for the lateral thigh measured from the hip joint to the knee joint split line in indicated at 19 cun however considering the fact that the hip joint cannot be located on the surface of the body through palpation we used X-ray to determine the inferior ridge of the anterior-superior iliac spine as a point which could be located on the surface of the body through touch. Recalculating then we determined the length from the inferior ridge of the anterior-superior iliac spine to the split line of the knee joint equivalent to 20 cun.
Although the standard medial and lateral scale is of different lengths we indicated the same scale. By proportionally distributing the acupuncture points between standard points it is possible to determine point locations.

We have investigated that individual properties and irritability to the electrical stimulation of Wenliu (Li-7) were determined by acupuncture of Hegu (Li-4) and Quchi (Li-11) as the strength-duration relations.
Results showed that reobase (27.8±1.09V, n=114), utilization time (1.38±0.13ms, n=114) and chronaxie (0.031±0.002ms, n=114), were interestingly similar as previous results of in vitro studies.
Value of chronaxie of female subjects (0.021±0.001ms, n=21) was significantly lower than male (0.053±0.010ms, n=36). So that acupuncture stimulation influenced to the chronaxie.
Hegu stimulation significantly (p<0.05) shortend than Quchi stimulation as compared to intact control group.
These results might be suggested that it has to considered responses to stimulation in the sex differences when determination of acupuncture effects in the clinical and/or research studies.

BACKGROUND/AIMS: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.METHODS: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018.RESULTS: Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn’s disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group.CONCLUSIONS: In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease.
Asian Continental Ancestry Group ; Colitis, Ulcerative ; Drug-Related Side Effects and Adverse Reactions ; Follow-Up Studies ; Humans ; Incidence ; Inflammatory Bowel Diseases ; Infliximab ; Japan ; Necrosis ; Prospective Studies

BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. METHODS: In this randomized, double-blind, placebo-controlled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). RESULTS: Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. CONCLUSIONS: Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.
Asian Continental Ancestry Group ; Colitis, Ulcerative ; Follow-Up Studies ; Humans ; Japan ; Leukoencephalopathy, Progressive Multifocal ; Ulcer